15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering Mirum Pharmaceuticals Inc, 13 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $95.00 to $150.00, a moderate spread. The average target of $132.85 sits 35% above the current $98.32. The rating mix has stayed broadly stable, with Buy-side ratings easing from 15 to 13 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.61 next quarter toward $-0.35 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Strong Buy
Strong Buy00%
Buy13100%
Hold00%
Sell00%
Strong Sell00%
Based on 13 analysts giving stock ratings to Mirum Pharmaceuticals Inc.
As of Sep, 13 of 13 firms rate MIRM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MIRM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.61
Range $-0.88 – $-0.34 · 2 analysts · +408% YoY
Next period, 2 analysts expect Mirum Pharmaceuticals Inc to earn $-0.61 a share (range $-0.88 – $-0.34), versus $-0.12 a year earlier. Full-year consensus is $-15.14, growing to $-0.35 the year after.
REVENUE · NEXT QUARTER
$183.2M
Range $176.6M – $189.2M · 2 analysts · +23% YoY
Revenue is expected to reach $183.2M (range $176.6M – $189.2M), +23.0% year-over-year. Full-year consensus is $696.6M, rising to $816.0M next year.
Top analysts covering Mirum Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MIRM.
#1
Jonathan Wolleben
JMP Securities · Rank #29
Buy
$146.00+48.5% to target
Overall win rate
47%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #71
Buy
$125.00+27.1% to target
Overall win rate
53%
+ Follow
#3
Josh Schimmer
Cantor Fitzgerald · Rank #162
Buy
$95.00-3.4% to target
Overall win rate
38%
+ Follow
#4
Yigal Nochomovitz
Citigroup · Rank #245
Buy
$145.00+47.5% to target
Overall win rate
41%
+ Follow
#5
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #252
Buy
$140.00+42.4% to target
Overall win rate
38%
+ Follow
MIRM stock forecast FAQ
What is MIRM's average 12-month price target?+
The 13 analysts with a live target average $132.85 for Mirum Pharmaceuticals Inc over the next 12 months, ranging from a $150.00 high to a $95.00 low.
Is MIRM stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 13 analyst ratings, 13 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MIRM?+
The Street-high target is $150.00 (Morgan Stanley), and the Street-low is $95.00 (Cantor Fitzgerald). The average of all 13 active targets is $132.85.
How many Wall Street analysts cover MIRM?+
13 analysts have an active rating on Mirum Pharmaceuticals Inc, and 13 firms carry a live 12-month price target.
Who is the most accurate analyst covering MIRM?+
Among analysts who currently cover MIRM, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #29). Their current call is Buy with a $146.00 target.
What is Mirum Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.61 per share (range $-0.88 – $-0.34) across 2 analysts. Full-year EPS is projected at $-15.14, rising to $-0.35 the following year.
How much revenue is Mirum Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $183.2M (range $176.6M – $189.2M). Full-year revenue is projected at $696.6M, growing to $816.0M next year.
Have analysts been upgrading or downgrading MIRM lately?+
As of Sep, 13 of 13 firms rate MIRM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MIRM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
